80S Ribosome · PROTEIN NUCLEIC-ACID COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-1480S Ribosome shows approved-linked disease relevance led by Becker muscular dystrophy. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P08865. Start with Becker muscular dystrophy, then reuse UniProt P08865 as the stable protein anchor across project notes and exports.
Start with Becker muscular dystrophy, then reuse UniProt P08865 as the stable protein anchor across project notes and exports.
80S Ribosome shows approved-linked disease relevance led by Becker muscular dystrophy. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Becker muscular dystrophy because it currently carries approved-linked support. Linked drugs include ATALUREN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxySmall ribosomal subunit protein uS2
Review this target as 80S Ribosome, mapped to UniProt P08865. ChEMBL maps the protein component as Small ribosomal subunit protein uS2. Sequence length is 295 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats 80S Ribosome as ChEMBL target CHEMBL3987582, mapped to UniProt P08865. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether 80S Ribosome is the right protein anchor across sources, using UniProt P08865 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Becker muscular dystrophy is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | 80S Ribosome |
| Target Type | PROTEIN NUCLEIC-ACID COMPLEX |
| Organism | Homo sapiens |
| UniProt | P08865 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Small ribosomal subunit protein uS2 |
| UniProt Accession | P08865 |
| Component Type | Protein |
| Sequence Length | 295 aa |
Small ribosomal subunit protein uS2
Review this target as 80S Ribosome, mapped to UniProt P08865. ChEMBL maps the protein component as Small ribosomal subunit protein uS2. Sequence length is 295 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
80S Ribosome shows approved-linked disease relevance led by Becker muscular dystrophy. 5 more disease programs remain visible in the same review block.
Start review with Becker muscular dystrophy because it currently carries approved-linked support. Linked drugs include ATALUREN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4109308 | 6.52 | IC50 | 300.0 | Preclinical |
| CHEMBL4574496 | 6.42 | IC50 | 380.0 | Preclinical |
| CHEMBL4126894 | 6.41 | IC50 | 390.0 | Preclinical |
| CHEMBL4114159 | 6.39 | IC50 | 410.0 | Preclinical |
| CHEMBL4126496 | 6.35 | IC50 | 450.0 | Preclinical |
| CHEMBL4560206 | 6.3 | IC50 | 500.0 | Preclinical |
| CHEMBL4130157 | 6.16 | IC50 | 690.0 | Preclinical |
| CHEMBL4108338 | 6.15 | IC50 | 710.0 | Preclinical |
| CHEMBL4107559 | 6.07 | IC50 | 850.0 | Preclinical |
| CHEMBL4533299 | 6.07 | IC50 | 850.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 80 | 26 | 5.8 |
| subcellular format | 7 | 14 | 5.0 |
| assay format | 2 | 2 | 4.7 |